Thursday, February 13, 2020 1:15:16 PM
Whatever cancer tech comes along - this drug is going to be useful... note how it is testing for *synergies* with existing treatments - the synergies are being proven right now!
Those treatments will come and go - but the drug(s) TROV is working on will remain useful for generations of cancer treatments to come... the sticking point was *safety* of PLK1 inhibition - it looks like TROV has proven safety, well enough that phase 3 is pretty well certain... being that TROV is evolving upon other companies drugs touted as highly effective but carrying bad side effects/that TROV has *resolved*, the pathway from here becomes much more clear (WAY up!).
This is worth *billions*, the price action until buyout is basically irrelevant at this point... not holding till then would likely be most regretful... very true that this thing has been pumped and dumped into oblivion - but in very true biotech fashion we very well could be in the early stages of what will ultimately be a massive windfall.
Recent CRDF News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:55 PM
- Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:13 PM
- Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/17/2024 10:10:38 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 08:06:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:03:35 PM
- Cardiff Oncology to Present at the Jefferies Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:05:00 PM
- Cardiff Oncology to Present at Upcoming Investor Conferences in May • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study • GlobeNewswire Inc. • 04/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:40 PM
- Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:07:00 PM
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC • GlobeNewswire Inc. • 02/29/2024 09:06:00 PM
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:00:21 PM
- Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:01:34 PM
- Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research • PR Newswire (US) • 01/17/2024 03:30:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM